• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, April 1, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Researchers compare drugs for treating severe hypertension in pregnancy

Bioengineer by Bioengineer
July 5, 2018
in Health
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A recent meta-analysis of published studies has compared the efficacy and safety of antihypertensive drugs during pregnancy.

In the British Journal of Clinical Pharmacology, investigators reported similar efficacy between nifedipine, hydralazine, and labetalol, and negligible differences were observed in their safety profile. The available evidence was inadequate for other drugs. Moderate quality of evidence was observed for direct comparison estimates between labetalol and hydralazine, but was either low or very low for other comparisons.

Labetalol, hydralazine, and nifedipine are likely comparable for treating acute-onset, severe hypertension in pregnancy, noted the authors, Dr. Kannan Sridharan and Prof. Reginald Sequeira, of Arabian Gulf University, in Bahrain.

###

Media Contact

Josh Glickman
[email protected]
201-748-6572

http://newsroom.wiley.com/

http://dx.doi.org/10.1111/bcp.13649

Share12Tweet8Share2ShareShareShare2

Related Posts

FOLR3 and Neutrophils Worsen Sepsis Inflammation

April 1, 2026

NIH Scientists Develop Pain-Relief Drug with Low Addiction Risk

April 1, 2026

Impact of AI-Powered Scribes on Clinician Time and Patient Visit Volume

April 1, 2026

Dorsoventral Hippocampus Reactivates After Aversive Sleep

April 1, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    Revolutionary AI Model Enhances Precision in Detecting Food Contamination

    96 shares
    Share 38 Tweet 24
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1006 shares
    Share 398 Tweet 249
  • Promising Outcomes from First Clinical Trials of Gene Regulation in Epilepsy

    51 shares
    Share 20 Tweet 13
  • Popular Anti-Aging Compound Linked to Damage in Corpus Callosum, Study Finds

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Dopamine Drives Dynamic Social Specialization

FOLR3 and Neutrophils Worsen Sepsis Inflammation

Manchester Professor Named Expert Reviewer for Government Nuclear Decommissioning Review

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.